FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jeroen-Paul van der Post

Research Profile

Procedures

Disorders

Concepts & Ideas

Chemicals & Drugs

Physiology

Co-author Network

Publications

TOP 3
S L de Haas; Saco J de Visser; Jeroen-Paul van der Post; Rik C Schoemaker; Kristien van Dyck; M Gail Murphy; Marina De Smet; L K Vessey; R Ramakrishnan; L Xue; Adam Cohen; J M A van Gerven
Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers.
S L de Haas; Saco J de Visser; Jeroen-Paul van der Post; M de Smet; Rik C Schoemaker; B Rijnbeek; Adam Cohen; Jose M Vega; Nancy G B Agrawal; Thanh V Goel; Richard C Simpson; L K Pearson; S Li; Michael Hesney; M Gail Murphy; J M A van Gerven
Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.
Jeroen-Paul van der Post; Saco J de Visser; Marieke L de Kam; M Woelfler; Dana C Hilt; James J Vornov; Eric Burak; Enoch Bortey; Barbara Slusher; T Limsakun; Adam Cohen; J M A van Gerven
The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jeroen-Paul van der Post (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: S L de Haas; Saco J de Visser; Jeroen-Paul van der Post; Rik C Schoemaker; Kristien van Dyck; M Gail Murphy; Marina De Smet; L K Vessey; R Ramakrishnan; L Xue; Adam Cohen; J M A van Gerven
Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers.
Journal of psychopharmacology (Oxford, England) 2008;22(1):24-32.
2007: S L de Haas; Saco J de Visser; Jeroen-Paul van der Post; M de Smet; Rik C Schoemaker; B Rijnbeek; Adam Cohen; Jose M Vega; Nancy G B Agrawal; Thanh V Goel; Richard C Simpson; L K Pearson; S Li; Michael Hesney; M Gail Murphy; J M A van Gerven
Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.
Journal of psychopharmacology (Oxford, England) 2007;21(4):374-83.
2005: Jeroen-Paul van der Post; Saco J de Visser; Marieke L de Kam; M Woelfler; Dana C Hilt; James J Vornov; Eric Burak; Enoch Bortey; Barbara Slusher; T Limsakun; Adam Cohen; J M A van Gerven
The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.
British journal of clinical pharmacology 2005;60(2):128-36.
2004: Jeroen-Paul van der Post; Saco J de Visser; Rik C Schoemaker; Adam Cohen; J M A van Gerven
Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients.
Journal of psychopharmacology (Oxford, England) 2004;18(2):221-7.
2004: Jeroen-Paul van der Post; P P de Waal; Marieke L de Kam; Adam Cohen; J M A van Gerven
No evidence of the usefulness of eye blinking as a marker for central dopaminergic activity.
Journal of psychopharmacology (Oxford, England) 2004;18(1):109-14.
2003: Saco J de Visser; Jeroen-Paul van der Post; P P de Waal; F Cornet; Adam Cohen; J M A van Gerven
Biomarkers for the effects of benzodiazepines in healthy volunteers.
British journal of clinical pharmacology 2003;55(1):39-50.
2002: Jeroen-Paul van der Post; L A W Noordzij; Marieke L de Kam; G J Blauw; Adam Cohen; J M A van Gerven
Evaluation of tests of central nervous system performance after hypoxemia for a model for cognitive impairment.
Journal of psychopharmacology (Oxford, England) 2002;16(4):337-43.
2002: Saco J de Visser; Jeroen-Paul van der Post; Loyd Nanhekhan; Rik C Schoemaker; Adam Cohen; J M A van Gerven
Concentration-effect relationships of two rilmenidine single-dose infusion rates in hypertensive patients.
Clinical pharmacology and therapeutics 2002;72(4):419-28.
2002: Jeroen-Paul van der Post; M T Schram; Rik C Schoemaker; Monique S M Pieters; Eliane Fuseau; A Pereira; S Baggen; Adam Cohen; J M A van Gerven
CNS effects of sumatriptan and rizatriptan in healthy female volunteers.
Cephalalgia : an international journal of headache 2002;22(4):271-81.
2002: Harm J Gijsman; J M A van Gerven; Marieke L de Kam; Rik C Schoemaker; Monique S M Pieters; Margo Weemaes; Roel de Rijk; Jeroen-Paul van der Post; Adam Cohen
Placebo-controlled comparison of three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers.
Journal of clinical psychopharmacology 2002;22(2):183-9.
2001: Saco J de Visser; Jeroen-Paul van der Post; Monique S M Pieters; Adam Cohen; J M A van Gerven
Biomarkers for the effects of antipsychotic drugs in healthy volunteers.
British journal of clinical pharmacology 2001;51(2):119-32.